Rapid communication Open Access
Like 0


German national surveillance data analysis shows that hospitalisation odds associated with Omicron lineage BA.1 or BA.2 infections are up to 80% lower than with Delta infection, primarily in ≥ 35-year-olds. Hospitalised vaccinated Omicron cases’ proportions (2.3% for both lineages) seemed lower than those of the unvaccinated (4.4% for both lineages). Independent of vaccination status, the hospitalisation frequency among cases with Delta seemed nearly threefold higher (8.3%) than with Omicron (3.0% for both lineages), suggesting that Omicron inherently causes less severe disease.


Article metrics loading...

Loading full text...

Full text loading...



  1. Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022;603(7902):679-86.  https://doi.org/10.1038/s41586-022-04411-y  PMID: 35042229 
  2. Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. 2022;376(6593):eabn4947.  https://doi.org/10.1126/science.abn4947  PMID: 35289632 
  3. Nishiura H, Ito K, Anzai A, Kobayashi T, Piantham C, Rodríguez-Morales AJ. Relative Reproduction Number of SARS-CoV-2 Omicron (B.1.1.529) Compared with Delta Variant in South Africa. J Clin Med. 2021;11(1):30.  https://doi.org/10.3390/jcm11010030  PMID: 35011781 
  4. Yamasoba D, Kimura I, Nasser H. Virological characteristics of SARS-CoV-2 BA.2 variant. bioRxiv. 2022; DOI:  https://doi.org/10.1101/2022.02.14.480335 
  5. Robert Koch Institut (RKI). SARS-CoV-2 Sequenzdaten aus Deutschland (2022-04-29). Zenodo; 2022. [data]. DOI:  https://doi.org/10.5281/zenodo.6503290 
  6. Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022;399(10323):437-46.  https://doi.org/10.1016/S0140-6736(22)00017-4  PMID: 35065011 
  7. Iuliano AD, Brunkard JM, Boehmer TK, Peterson E, Adjei S, Binder AM, et al. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):146-52.  https://doi.org/10.15585/mmwr.mm7104e4  PMID: 35085225 
  8. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. , COVID-19 Genomics UK (COG-UK) consortium. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303-12.  https://doi.org/10.1016/S0140-6736(22)00462-7  PMID: 35305296 
  9. Peralta-Santos A, Rodrigues EF, Moreno J, Ricoca V, Casaca P, Fernandes E, et al. Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2). medRxiv. 2022Jan23;2022.01.20.22269406. DOI:
  10. Veneti L, Bøås H, Bråthen Kristoffersen A, Stålcrantz J, Bragstad K, Hungnes O, et al. Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. Euro Surveill. 2022;27(4):2200077.  https://doi.org/10.2807/1560-7917.ES.2022.27.4.2200077  PMID: 35086614 
  11. Wolter N. JASSAT W, Group D-GA, Gottberg A von, Cohen C. Clinical severity of Omicron sub-lineage BA.2 compared to BA.1 in South Africa. medRxiv. 2022Feb19;2022.02.17.22271030. DOI:  https://doi.org/10.1101/2022.02.17.22271030 
  12. Fonager J, Bennedbæk M, Bager P, Wohlfahrt J, Ellegaard KM, Ingham AC, et al. Molecular epidemiology of the SARS-CoV-2 variant Omicron BA.2 sub-lineage in Denmark, 29 November 2021 to 2 January 2022. Euro Surveill. 2022;27(10):2200181.  https://doi.org/10.2807/1560-7917.ES.2022.27.10.2200181  PMID: 35272746 
  13. Robert Koch Institut (RKI). Wöchentlicher Lagebericht des RKI. Berlin: RKI; 17 Mar 2022. [Accessed 18 Mar 2022]. Available from: www.rki.de/covid-19-situationsbericht
  14. Department for Statistics South Africa. Mid-year population estimates 2019, STATISTICAL RELEASE P0302. 2019. [Accessed 30 May 2022]. Available from: https://www.statssa.gov.za/publications/P0302/P03022019.pdf
  15. German Federal Statistical Office. Population by age groups (as of 2011) - German Federal Statistical Office. [Accessed 30 May 2022]. Available from: https://www.destatis.de/EN/Themes/Society-Environment/Population/Current-Population/Tables/lrbev01.html
  16. Bager P, Wohlfahrt J, Bhatt S, Edslev SM, Sieber RN, Ingham AC, et al. Reduced Risk of Hospitalisation Associated With Infection With SARS-CoV-2 Omicron Relative to Delta: A Danish Cohort Study. SSRN Electron J. 2022Jan20;  https://doi.org/10.2139/ssrn.4008930 
  17. Castagnoli R, Votto M, Licari A, Brambilla I, Bruno R, Perlini S, et al. Severe Acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: A systematic review. JAMA Pediatr. 2020;174(9):882-9.  https://doi.org/10.1001/jamapediatrics.2020.1467  PMID: 32320004 
  18. Schilling J, Tolksdorf K, Marquis A, Faber M, Pfoch T, Buda S, et al. , RKI COVID-19 Study Group. Die verschiedenen Phasen der COVID-19-Pandemie in Deutschland: Eine deskriptive Analyse von Januar 2020 bis Februar 2021. [The different periods of COVID-19 in Germany: a descriptive analysis from January 2020 to February 2021]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2021;64(9):1093-106.  https://doi.org/10.1007/s00103-021-03394-x  PMID: 34374798 
  19. Neuhauser H, Buttmann-Schweiger N, Ellert U, Fiebig J, Hövener C, Offergeld R, et al. Seroepidemiological studies on SARS-CoV-2 in samples from the general population and blood donors in Germany-findings up to August 2021. Epidemiol Bull. 2021;37:03-12.  https://doi.org/10.25646/9159 

Data & Media loading...

Supplementary data

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error